

ACL Laboratories COVID-19 and Influenza Activity Report

Updated: Aug 22, 2021




RESPIRATORY PATHOGEN PANEL Aug, 2021

Positivity Rate (%)


MONTH	FLU A	FLU H1 (H1-A)	2009 H1N1 (H1-B)	H3	FLU B	RSV A	RSV B	RSV A/B	PARA 1	PARA 2	PARA 3	PARA 4	COR 229E	COR NL63	COR OC43	COR HKU1	META	E/R	ADENO	BOCA	LEG	CHL	MYCO
JAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.1	0.7	0.3	0.0	0.0	0.0	
FEB	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.2	6.1	0.2	0.3	0.0	0.0	0.0
MAR	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.3	0.4	0.1	0.1	0.3	0.1	1.4	0.9	0.1	0.4	12.2	1.2	0.3	0.0	0.1	0.1
APR	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.2	0.5	0.0	0.0	2.5	2.9	0.0	0.8	15.3	1.4	1.2	0.0	0.0	0.0
MAY	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.7	3.9	0.0	0.2	1.4	3.9	0.0	0.0	14.4	1.7	1.4	2.7	0.0	0.1
JUN	0.0	0.0	0.0	0.0	0.0	0.1	1.8	1.9	0.0	0.3	9.6	0.0	0.3	0.4	2.4	0.0	0.1	15.8	1.1	1.8	0.0	0.0	0.1
JUL	0.0	0.0	0.0	0.0	0.0	1.0	7.2	8.2	0.1	0.5	12.9	0.0	0.1	0.4	1.4	0.0	0.5	18.9	1.6	4.4	4.3	0.0	0.0
AUG	0.0	0.0	0.0	0.0	0.6	12.5	13.1	0.0	1.0	7.3	0.1	0.0	0.2	0.6	0.0	0.4	14.0	1.1	3.4	0.0	0.0	0.0	
SEP																							
OCT																							
NOV																							
DEC																							


Increased prevalence of viruses: **RSV (type B), Parainfluenza 3 and Rhinovirus.**

Parainfluenza 3 POSITIVITY RATE 2021 (%)



RPP RSV POSITIVITY RATE 2021 (%)







ACL RSV PCR by Cepheid - assay was started on Aug 8th 2021

CDC Data RSV pos rate for Region 5 Chicago - (PCR - 16%, Antigen - 31% ↑)

Total PCR Tests




Total Antigen Tests




SARS-COV-2					Influenza - no activity				RSV (Antigen+PCR)			
Week	IL % SCVPCR	WI % SCVPCR	IL % COVAG	WI % COVAG	IL % FLUPCR	WI % FLUPCR	IL % FLUAG	WI % FLUAG	IL % RSVAG	WI % RSVAG	IL % RSVPCR	WI % RSVPCR
Aug 22	6.0	7.3	13.5	15.9	0	0			20.0	25.9	32.5	20.6
Aug 15	6.6	6.8	9.8	18.0	0	0	0	0	25.9	23.5	27.0	16.7
Aug 8	6.8	7.4	9.8	15.8	0	0	0	0	14.6	22.7	25.7	16.9
Aug 1	3.8	6.9	10.5	17.6	0	0	0	0	32.1	22.0	0.0	0.0
Jul 25	2.7	4.1	8.0	11.8	0	0	0	0	15.5	16.7	0.0	0.0
Jul 18	1.8	2.6	1.4	7.2	0	0	0	0	15.6	21.6	0.0	0.0
Jul 11	1.6	1.6	1.0	5.0	0	0	0	0	16.7	17.4	0.0	0.0
Jul 4	1.6	1.4	0.0	3.0	0	0	0	0	15.5	15.5	0.0	0.0
Jun 27	1.7	1.5	1.5	2.8	0	0	0	0	11.1	8.3	0.0	0.0
Jun 20	1.5	1.2	1.5	1.1	0	0	0	0	7.1	3.2	0.0	0.0
Jun 13	1.6	1.2	1.4	2.7	0	0	0	0	8.6	3.7	0.0	0.0
Jun 06	2.5	1.6	2.6	2.7	0	0	0	0	5.0	0.0	0.0	0.0


ACL RSV tests results are consistent with “atypical” summer RSV outbreak




ACL COVAG and SCVPCR - Pos rate (%) - Aug 22, 2021



Aug 18, 2021 - daily COVID-19 cases in US - CDC



Aug 14, 2021 – SARS-CoV-2 circulating in the US (~98.8% % Delta variants)



US vaccination status CDC | Data as of: Aug 19, 2021

359,623,380

Vaccines Administered

199,887,548

People who received at least one dose

169,592,873

People who are fully vaccinated*


60.2%

Percentage of the US population that has received at least one dose


51.1%

Percentage of the US population that has been fully vaccinated*


Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, September 27, 2020 – August 14, 2021




2020-21 Influenza Season Week 32 ending Aug 14, 2021



CSF targets positivity rate is 10% (*the most prevalent is HSV1*)



The most prevalent GI bacterial target is (Cryptosporidium 1.8%)



The most prevalent GI viral target is – (Norovirus II – 0.3%)

ACL GPP - STOOL POSITIVE VIRAL TARGETS - Aug 22, 2021

